CHPG is a selective agonist of mGluR5. In BV2 microglial cells, it attenuates SO2-induced oxidative stress and inflammation through the TSG-6/NF-κB pathway.

CHPG (0.5?mM; 30?mins ) protects BV2 cells against SO2-induced apoptosis. CHPG (10-500?μM; 24?hours) significantly increases the cell viability and decreases the LDH release after SO2 derivatives treatment. CHPG (0.5?mM; 30?mins) treatment alone increases the expression of TSG-6 in both mRNA and protein levels [1].

CHPG (injection; 250 nM; for 7 days) reduces significantly cerebral lesion volume [2].

170846-74-9

C8H8ClNO3

201.61

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years